Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $60.0 million.

  • Gyre Therapeutics' Cash & Current Investments rose 138.99% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.1 million, marking a year-over-year increase of 41.21%. This contributed to the annual value of $26.7 million for FY2024, which is 20.28% down from last year.
  • Gyre Therapeutics' Cash & Current Investments amounted to $60.0 million in Q3 2025, which was up 10.38% from $54.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Cash & Current Investments registered a high of $131.0 million during Q1 2021, and its lowest value of $6.9 million during Q3 2023.
  • Its 3-year average for Cash & Current Investments is $29.4 million, with a median of $26.7 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 84.71% in 2023, then soared by 264.57% in 2024.
  • Gyre Therapeutics' Cash & Current Investments (Quarterly) stood at $49.4 million in 2021, then plummeted by 48.99% to $25.2 million in 2022, then skyrocketed by 33.10% to $33.5 million in 2023, then fell by 20.28% to $26.7 million in 2024, then soared by 138.99% to $60.0 million in 2025.
  • Its Cash & Current Investments stands at $60.0 million for Q3 2025, versus $54.4 million for Q2 2025 and $29.9 million for Q1 2025.